Inclusion Criteria:

- Patients who are not eligible for haematopoietic stem cell transplantation, who are
at least 18 years old (no age limit to top) and who have one of the following
diseases:

- myelodysplastic syndrome (MDS) with intermediate risk 2 or high risk according
to the International Prognostic Scoring System (IPSS)

- chronic myelomonocytic leukemia (CMML) with 10-29% marrow blasts without
myeloproliferative disorder

- acute myeloid leukemia (AML) with 20-30% blasts and multilineage dysplasia
according to classification of the World Health Organisation (WHO).

Exclusion Criteria:

- Contraindication according to the summary of product characteristics of Vidaza®

- Signed patient informed consent form is not available

- Patients with advanced malignant hepatic tumors

- Pregnant or nursing women, men and women (of childbearing age) who are unwilling to
apply a reliable method of contraception during and up to three months after
treatment with Azacitidine

- Necessary or planned treatment with other systemic cytostatics

- Known medical history of severe decompensatoric cardiac insufficiency

- Medical history of clinically unstable cardiac or pulmonary disease

- Known or suspected hypersensitivity to azacitidine or mannitol